A comparative, randomized, uncontrolled study of the effectiveness of two regimens for the treatment of clinical manifestations of laryngopharyngeal reflux without esophageal symptoms


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Background. Drug treatment of clinical manifestations of laryngopharyngeal reflux (LPR) without esophageal symptoms is an actual unsolved problem. Questions about the choice of the optimal treatment regimen, the choice of drugs, the use of proton pump inhibitors, their dosage and timing of treatment remain. Objective. Comparison of the results of treatment of LPR clinical manifestations without esophageal symptoms with two antireflux therapy regimens. Methods. TTwo study groups were randomly selected from patients with LPR symptoms without esophageal symptoms. The first group received monotherapy with omeprazole 20 mg 30 minutes before meals in the morning, Patients of the 2nd group received omeprazole 20 mg 30 minutes before meals in the morning, Gaviscon suspension 10 ml after meals and 1 time at night, nasal douche 2 times a day with saline NaCl solution 0.9%. Results. The quantitative assessment of symptoms according to the RSI questionnaire when prescribing the 2nd treatment regimen as early as 2 weeks after the start of treatment was statistically significantly lower than when prescribing the 1st treatment regimen. After 6 weeks, the quantitative assessment of symptoms according to the RSI questionnaire for both treatment regimens did not differ statistically significantly, but was statistically significantly less than at study entry. Changes during an objective examination of the ENT organs occured no earlier than the 6th week of antireflux therapy with both treatment regimens. Conclusion. Symptoms of LPR decreased statistically significantly faster with the use of the 2nd treatment regimen (omeprazole 20 mg in the morning 30 minutes before meals, gaviscon suspension 10 ml 3 times a day after meals and 1 time at night, nasal douche 2 times a day). A statistically significant improvement in the results of an objective examination of the ENT organs occurred by the 6th week when both treatment regimens were prescribed. Therefore, the minimum duration of antireflux therapy is 6 weeks.

Texto integral

Acesso é fechado

Sobre autores

Irina Angotoeva

Russian Medical Academy of Continuous Professional Education

Email: angotoeva@mail.ru
Cand. Sci. (Med.), Associate Professor, Department of Otorhinolaryngology Moscow, Russia

I. Loranskaya

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

S. Kosyakov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

Bibliografia

  1. Amirlak B, Mudd P.A. RefluxLaryngitis. Medscape. URL: http://emedicine.medscape.com/article/864864-overview (Access date: 01.09.17).
  2. Koufman S.A. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991;101(4 Pt 2 Suppl 53):1-78. doi: 10.1002/lary.1991.101.s53.1.
  3. Lechien S.R., Saussez S., Schindler A, et al. Clinical outcomes of laryngopharyngeal reflux treatment: A systematic review and meta-analysis. Laryngoscope. 2018 Dec 30. doi: 10.1002/lary.27591.
  4. Belafsky P.C., Postma G.N., Koufman S.A. Validity and reliability of the reflux symptom index (RSI). J Voice 2002;16(2):274-77. doi: 10.1016/s0892-1997(02)00097-8.
  5. Schenk B., Kuipers E., Klinkenberg-Knol E., et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol. 1997;92:1997-2000.
  6. Belafsky P.C., Postma G.N., Koufman J.A. The validity and reliability of the reflux finding score (RFS). Laryngoscope 2001;111(8):1313-17. doi: 10.1097/00005537-200108000-00001.
  7. Franco R.A., Deschler D.G., Sullivan D.J. Laryngopharyngeal reflux. Uptodate. URL: file:///Users/a69/Downloads/uptodate/UpToDate/contents/mobipreview.htm?33/10/33960 (Access date: 01.09.18).
  8. Lechien J.P., Bobin F., Darpi G., et al. Hypopharyngeal-Esophageal Impedance-pH Monitoring Profiles of Laryngopharyngeal Reflax Patients. Laryngoscope. 2021;131:268-76. Doi. org/10.1002/lary.28736.
  9. Koufman S.A., Aviv J.E., Casiano R.R., Shaw G.Y. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127(1):32-5. doi: 10.1067/mhn.2002.125760.
  10. Diamond L: Laryngopharyngeal reflux - it's not GERD. JAAPA 2005;18(8):50-3;127(1):32-5. doi: 10.1097/01720610-200508000-00008.
  11. Ford C.N. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294(12):1534-40. doi: 10.1001/jama.294.12.1534.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2022

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies